Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes

Oncogene

Volumn 34, Issue 28, 2015, Pages 3640-3650

  Cui, H ^a   Seubert, B ^a   Stahl, E ^b   Dietz, H ^b   Reuning, U ^a   Moreno Leon, L ^c,d   Ilie, M ^c,e   Hofman, P ^c,e   Nagase, H ^f   Mari, B ^c,d   Kruger A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WALTER SCHOTTKY INSTITUT   (Germany)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CNRS   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN210 MICRORNA, HUMAN; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; EXOSOME; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; EXOSOMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84940577028     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.300     Document Type: Article

References (76)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
3. Gupta GP, Massagué J. Cancer metastasis: Building a framework. Cell 2006; 127: 679-695.
4. Krüger A, Kates RE, Edwards DR. Avoiding spam in the proteolytic internet: Future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 2010; 1803: 95-102.
5. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys 2010; 1803: 55-71.
6. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011; 12: 233.
7. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci 2013; 71: 659-672.
8. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: Metalloproteinase-independent biological activities. Sci Signal 2008; 1: Re6.
9. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45: 291-338.
10. Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 2007; 67: 8615-8623.
11. Amour A, Knight C, Webster A, Slocombe P, Stephens P, Knäuper V et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473: 275-279.
12. Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005; 99: 656-663.
13. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 1999; 20: 1311-1316.
14. Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääkkö P, Risteli J, Kinnula VL et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-1637.
15. Pesta M, Kulda V, Kucera R, Pesek M, Vrzalova J, Liska V et al. Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res. 2011; 31: 4031-4038.
16. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: A potential prognostic biomarker. Ann Clin Lab Sci 2006; 36: 23-30.
17. Ilie M, Lassalle S, Long-Mira E, Hofman V, Zangari J, Bénaim G et al. In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predict aggressive behaviour. Virchows Arch 2013; 463: 437-444.
18. Jung K-K, Liu X-W, Chirco R, Fridman R, Kim H-RC. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25: 3934-3942.
19. Liu X-W, Bernardo MM, Fridman R, Kim H-RC. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003; 278: 40364-40372.
20. Taube ME, Liu XW, Fridman R, Kim HRC. TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27KIP1 protein. Oncogene 2006; 25: 3041-3048.
21. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: A potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898-906.
22. Li G, Fridman R, Kim HRC. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59: 6267-6275.
23. Schelter F, Halbgewachs B, Bäumler P, Neu C, Görlach A, Schrötzlmair F et al. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1?. Clin Exp Metastasis 2011; 28: 91-99.
24. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
25. Wilczynski J, Duechler M, Czyz M. Targeting NF-?B and HIF-1 pathways for the Treatment of cancer: Part II. Arch Immunol Ther Exp (Warsz) 2011; 2011: 301-307.
26. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 2002; 295: 858-861.
27. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402.
28. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-? to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
29. Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: The master hypoxamir. Microcirculation 2012; 19: 215-223.
30. Chan SY, Loscalzo J. MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle 2010; 9: 1072-1083.
31. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK et al. Hypoxiainducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-867.
32. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283: 15878-15883.
33. Alaiti MA, Ishikawa M, Masuda H, Simon DI, Jain MK, Asahara T et al. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med 2012; 16: 2413-2421.
34. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008; 7: 255-264.
35. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009; 284: 33161-33168.
36. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72: 4629-4641.
37. Zhang Z, Sun H, Dai H, Walsh R, Imakura M, Schelter J et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009; 8: 2756-2768.
38. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2010; 18: 465-478.
39. Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1-alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 2011; 31: 2696-2706.
40. Wang A, Flach H, Onizawa M, Wei L, McManus M, Weiss A. Negative regulation of Hif1a expression and TH17 differentitation by the hypoxia-regulated microRNA miR-210. Nat Immunol 2014; 15: 393-401.
41. Semenza GL. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-56.
42. King H, Michael M, Gleadle J. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012; 12: 421-431.
43. Shimoda M, Khokha R. Proteolytic factors in exosomes. Proteomics 2013; 13: 1624-1636.
44. Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: Molecular mechanisms and roles in immune responses. Traffic 2011; 12: 1659-1668.
45. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
46. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxiadependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013; 110: 7312-7317.
47. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 2011; 286: 420-428.
48. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S et al. Hypoxia-inducible miR-210 augments the metastatic potential of tumor cells by targeting VMP1 in hepatocellular carcinoma. Hepatology 2011; 54: 2064-2075.
49. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009; 69: 1221-1229.
50. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJP. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 8097-8102.
51. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002; 4: S51-S61.
52. Jung Y, Liu X, Chirco R, Warner R, Fridman R, Kim H. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS ONE 2012; 7: E38773.
53. Lu Y, Liu S, Zhang S, Cai G, Jiang H, Su H et al. Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol Cells 2011; 31: 225-230.
54. Huang X, Le Q-T, Giaccia AJ. MiR-210-micromanager of the hypoxia pathway. Trends Mol Med 2010; 16: 230-237.
55. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46.
56. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
57. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y et al. Let-7 microRNA familiy is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 2010; 5: E13247.
58. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010; 9: 1085-1099.
59. Gouyer Vr, Conti M, Devos P, Zerimech F, Copin MC, Créme E et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 2005; 103: 1676-1684.
60. Cui H, Grosso S, Schelter F, Mari B, Krüger A. On the pro-metastatic stress response to cancer therapies: Evidence for a positive co-operation between TIMP-1, HIF-1alpha, and miR-210. Front Pharmacol 2012; 3: 134.
61. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
62. Liu H, Chen B, Lilly B. Fibroblasts potentiate blood vessel formation partially through secreted factor of TIMP-1. Angiogenesis 2008; 11: 223-234.
63. Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998; 5: 81-87.
64. De Lorenzo MS, Ripoll GV, Yoshiji H, Yamazaki M, Thorgeirsson UP, Alonso DF et al. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In vivo 2003; 17: 45-50.
65. Salomon C, Ryan J, Sobrevia L, Kobayashi M, Ashman K, Mitchell M et al. Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PloS ONE 2013; 8: E68451.
66. Xiao F, Qiu H, Zhou L, Shen X, Yang L, Ding K. WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cells (HMEC-1) tube formation. Glycobiology 2013; 23: 524-535.
67. Ghajar C, Peinado H, Mori H, Matei I, Evason K, Brazier H et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-817.
68. Xia Y, Yeddula N, Leblanc M, Ke E, Zhang Y, Oldfield E et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 2012; 14: 257-265.
69. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
70. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009; 10: 273-284.
71. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 2013; 4: E544.
72. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
73. Hauser S, Bickel L, Weinspach D, Gerg M, Schäfer MK, Pfeifer M et al. Full-length L1CAM and not its delta2delta27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One 2011; 6: E18989.
74. Schambach A, Mueller D, Galla M, Verstegen MMA, Wagemaker G, Loew R et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 2006; 13: 1524-1533.
75. Lässer C, Eldh M, Lötvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp 2012 e3037.
76. Arnaoutova I, Kleinman HK. In vitro angiogenesis: Endothelial cell tube formation on gelled basement membrane extract. Nature Protoc 2010; 5: 628-635.